In a report released today, Arlinda Lee from Canaccord Genuity maintained a Buy rating on Summit Therapeutics (NASDAQ: SMMT), with a price target of $3. The company’s shares opened today at $2.45, close to its 52-week low of $2.17.
According to TipRanks.com, Lee is a 2-star analyst with an average return of 0.5% and a 42.4% success rate. Lee covers the Healthcare sector, focusing on stocks such as Eloxx Pharmaceuticals Inc, Karyopharm Therapeutics, and Aquinox Pharmaceuticals.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Summit Therapeutics with a $8 average price target, representing a 226.5% upside. In a report released today, H.C. Wainwright also maintained a Buy rating on the stock with a $3 price target.
.
See today’s analyst top recommended stocks >>
The company has a one-year high of $16.86 and a one-year low of $2.17. Currently, Summit Therapeutics has an average volume of 80.55K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Summit Therapeutics Plc is a holding company, which engages in the discovery, development, and commercialization of novel medicines. It focuses on the genetic disease duchenne muscular dystrophy, and the infectious disease clostridium difficile infection.